Last reviewed · How we verify
Benzalkonium Chloride Solution
Benzalkonium Chloride Solution, marketed by Lustre Pharmaceutical Lab Co., Ltd, is positioned in the bacterial skin elimination segment. A key strength is its protected market position with a key composition patent expiring in 2028. The primary risk is the lack of reported revenue and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Benzalkonium Chloride Solution |
|---|---|
| Also known as | Youkeshi, You Ke Shi, BlastX |
| Sponsor | Lustre Pharmaceutical Lab Co., Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Bacterial skin elimination
Common side effects
Key clinical trials
- Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) (PHASE2)
- Nasal Decongestant to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having Anesthesia. (PHASE4)
- Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant (PHASE2)
- SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People (PHASE1)
- Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom (PHASE2)
- Sublingual vs IV Atropine Bioavailability Study (PHASE1)
- Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos. (PHASE4)
- Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |